Publications
For complete list of publications:
Google Scholar
ORCID
Publons
PubMed
Publications (# equal contribution * Corresponding author)
Year 2023
121. Tan B,# Zhang X,# Ansari A,# Jadhav P,# Tan H, Li K, Chopra A, Ford A, Chi X, Ruiz FX,* Arnold E,* Deng X,* Wang J.* Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024 Mar 29;383(6690):1434-1440. doi: 10.1126/science.adm9724. Epub 2024 Mar 28. PMID: 38547259. Link
120. Jadhav P,# Huang B,# Osipiuk J,# Zhang X, Tan H, Tesar C, Endres M, Jedrzejczak R, Tan B, Deng X, Joachimiak A,* Cai J,* Wang J.* Structure-based design of SARS-CoV-2 papain-like protease inhibitors. Eur J Med Chem. 2023 Dec 5;264:116011. doi: 10.1016/j.ejmech.2023.116011. Epub ahead of print. PMID: 38065031. Link
119. Tan B, Liu C, Li K, Jadhav P, Lambrinidis G, Zhu L, Olson L, Tan H, Wen Y, Kolocouris A, Liu W, Wang J* Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors. J Med Chem 2023 https://doi.org/10.1021/acs.jmedchem.3c00995. Link
118. Ou J, Lewandowski EM, Hu Y, Lipinski AA, Aljasser A, Colon-Ascanio M, Morgan RT, Jacobs LMC, Zhang X, Bikowitz MJ, Langlais PR, Tan H, Wang J,* Chen Y,* Choy JS.* A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations. PLoS Pathog. 2023 Aug 31;19(8):e1011592. doi: 10.1371/journal.ppat.1011592. Epub ahead of print. PMID: 37651467. Link
117. Somberg NH, Medeiros-Silva J, Jo H, Wang J, DeGrado WF, Hong M.* Hexamethylene Amiloride Binds the SARS-CoV-2 Envelope Protein at the Protein-Lipid Interface. Protein Sci. 2023 Aug 25:e4755. doi: 10.1002/pro.4755. Epub ahead of print. PMID: 37632140. Link
116. Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X,* Chen Y,* Wang J.* Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent. Sci. 2023. Link
115. Tan B, Sacco M, Tan H, Li K, Joyce R, Zhang X, Chen Y, Wang J.* Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. Eur J Med Chem. 2023 Jul 19;259:115667. doi: 10.1016/j.ejmech.2023.115667. Epub ahead of print. PMID: 37482021. Link
114. Hoffman A, Stampolaki M, Tzitzoglaki C, Schmerer P, Ma C, Döring K, Turcu A, Wang J, Vazquez S, Schmidtke M, Kolokouris A,* Stylianakis I, Movellan KT, Andreas L, Becker S. Adamantyl Amines Activity Study Against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple blocker Explored with MD simulations and Solid state NMR. ChemMedChem. 2023 Jun 28:e202300182. doi: 10.1002/cmdc.202300182. Epub ahead of print. PMID: 37377066.
113. Tan H, Hu Y, Wang J.* FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro. STAR Protoc. 2023 May 4;4(2):102323. doi: 10.1016/j.xpro.2023.102323. Epub ahead of print. PMID: 37329507; PMCID: PMC10156985. Link
112. Frost J, Rudy MJ, Leser JS, Tan H, Hu Y, Wang J, Clarke P, Tyler KL.* Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis. J Virol. 2023 May 8:e0015623. doi: 10.1128/jvi.00156-23. Epub ahead of print. PMID: 37154751. Link
111. Wang J,* Shahed-Ai-Mahmud M, Chen A, Li K, Tan H, Joyce R. An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses. J Med Chem. (perspective) 2023 Mar 24. doi: 10.1021/acs.jmedchem.3c00069. Epub ahead of print. PMID: 36961984. Link
110. Wang L, Ma C, Sacco MD, Xue S, Mahmoud M, Calcul L, Chen Y,* Wang J,* Cai J.* Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold. Chemistry. 2023 Mar 15:e202300476. doi: 10.1002/chem.202300476. Epub ahead of print. PMID: 36920943. Link
109. Tan B, Joyce R, Tan H, Hu Y, Wang, J* SARS-CoV-2 main protease drug design, assay development, and drug resistance studies. Acc. Chem. Res. 2023, 56, 157-168. Link
Year 2022
108. Tzitzoglaki C, Hoffmann A, Turcu A, Schmerer P, Ma C, Laros G, Liolios C, Jose B, Wang J, Vazquez S, Schmidtke M,* Kolocouris A.* Amantaidne variant – Aryl conjugates that inhibit multiple M2 mutant – amantadine resistant influenza A viruses. Eur. J. Med. Chem. Rep. 2022, 6, 100083. Link
107. Joyce R, Hu V, Wang J*. The history, mechanism, and perspective of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res. 2022, 31, 1637-1646. (special issue in honor of Prof. Edmond J. LaVoie) Link
106. Potter C, Hu Y, Xiong Z, Wang J, McLeod E.* Point-of-care SARS-CoV-2 sensing using lens-free imaging and a deep learning-assisted quantitative agglutination assay. Lab Chip. 2022, 22, 3744-3754. Link
105. Sacco MD, Wang S, Adapa SR, Zhang X, Lewandowski EM, Gongora MV, Keramisanou D, Atlas ZD, Townsend JA, Gatdula JR, Morgan RT, Hammond LR, Marty MT, Wang J, Eswara PJ, Gelis I, Jiang RHY, Sun X,* Chen Y.* A unique class of Zn2+-binding serine-based PBPs underlies cephalosporin resistance and sporogenesis in Clostridioides difficile. Nat. Commun. 2022, 13, 4370. Link
104. Gomez K, Tang C, Tan B, Perez-Miller S, Ran D, Loya S, Calderon-Rivera A, Stratton H, Duran P, Masterson K, Gabrielsen A, Alsbiei O, Dorame A, Serafini M, Moutal A, Wang J,* Khanna R.* Stereospecific effects of benzimidazolonepiperidine compounds on T-type Ca2+ channels and pain. ACS Chem. Neurosci. 2022,13, 2035-2047. Link
103. Tan H, Hu Y, Jadhav P, Tan B, Wang J.* Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. (perspective) 2022, 65, 7561-7580. Link
102. Zhou X, Zhu L, Bondy C, Wang J, Luo Q, Chen Y.* AG1478 elicits a novel anti-influenza function via an EGFR-independent, GBF1-dependent pathway. Int. J. Mol. Sci. 2022, 23, 5557. Link
101. Tan H, Ma C, Wang J.* Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med. Chem. Res. 2022, 31, 1147-1153. (Special issue in honor of Prof. Laurence Hurley).
100. Wang J,* Li, H.* Editorial of Special Column on Antiviral Drug Discovery and Pharmacology. Acta Pharm. Sin. B 2022, 12, 1540-1541 Link
99. Ma C,# Hu Y,# Wang Y, Choza, J, Wang J.* Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor. ACS Infect Dis 2022, 8, 1022-1030. Link
98. Sacco M, Hu Y, Gongora M, Meilleur F, Kemp M, Zhang X, Wang J,* Chen Y.* The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small molecule drug inhibition. Cell Res. 2022, 32, 498-500. Link
97. Hu Y, Ma C, Wang J.* Cytopathic effect assay and plaque assay to evaluate in vitro activity of antiviral compounds against human coronaviruses 229E, OC43 and NL63. Bio-protocol 2022, 12, e4314. Link
96. Hu Y, Jo H, DeGrado WF, Wang J.* Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell. J. Med. Virol. 2022, 94, 2188-2200. Link
95. Ma C, Wang J.* Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors. ACS Pharmacol. Transl. Sci 2022, 5, 102-109. Link
Year 2021
94. Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, Choza J, Tan H, Jang J, Gongora MV, Zhang X, Zhang F, Xiang Y, Marty MT, Chen Y,* Wang J.* Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. J. Am. Chem. Soc. 2021, 143, 20697-20709. Link
93. Townsend JA, Sanders HM, Rolland AD, Park CK, Horton NC, Prell JS, Wang J, Marty MT.* Influenza AM2 Channel Oligomerization Is Sensitive to Its Chemical Environment. Anal. Chem. 2021, 93, 16273-16281. Link
92. Ma C, Tan H, Choza J, Wang Y, Wang J.* Validation and invalidation of SARS-CoV-2 main protease inhibitors using the FlipGFP and Protease-Glo luciferase assays. Acta Pharm. Sin. B 2022, 12, 1636-1651 Link
91. Boras B, Jones RM,* Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O’ Brien MN, O’Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, García-Sastre A, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 2021, 12, 6055. doi: 10.1038/s41467-021-26239-2. Link
90. Cáceres CJ, Hu Y, Cárdenas-García S, Tan H, Wu X, Carnaccini S, Gay LC, Geiger G, Ma C, Zhang QY, Rajao D, Perez DR,* Wang J.* Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerg. Microbes Infect. 2021, 10, 1832-1848. Link
89. Wang J,* Hu Y, Zheng, M. Enterovirus 71 antivirals: past, present, and future. Acta Pharm. Sin. B. 2022, 12, 1542-1566. Link
88. Thomaston JL, Samways ML, Konstantinidi A, Ma C, Hu Y, Bruce Macdonald HE, Wang J, Essex JW, DeGrado WF,* Kolocouris A.* Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity. Biochemistry. 2021, 60, 2471-2482. Link
87. Xia Z,# Sacco M,# Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y,* Wang J.* Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol. Transl. Sci. 2021, 4, 1408-1421. Link
86. Ma C,# Sacco MD,# Xia Z,# Lambrinidis G, Townsend JA, Hu Y, Meng X, Szeto T, Ba M, Zhang X, Gongora M, Zhang F, Marty MT, Xiang Y, Kolocouris A, Chen Y,* Wang J.* Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent. Sci. 2021, 7, 1245-1260. Link
85. Hu Y,# Kitamura N,# Musharrafieh R, Wang J.* Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein. J. Med. Chem. 2021, 64, 8755-9774. Link
84. Zhao H, Jiang S, Ye Z, Zhu H, Hu B, Meng P, Hu Y, Zhang H, Wang K,* Wang J,* Tian Y.* Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. Eur. J. Med. Chem. 2021, 221, 113567. Link
83. Cáceres CJ, Cardenas-Garcia S, Carnaccini S, Seibert B, Rajao DS, Wang J,* Perez DR.* Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci. Rep. 2021, 11, 9609. Link
82. Kitamura N, Sacco MD, Ma C, Hu Y, Townsend JA, Meng X, Zhang F, Zhang X, Ba M, Szeto T, Kukuljac A, Marty MT, Schultz D, Cherry S, Xiang Y, Chen Y,* Wang J.* (2021) Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J. Med. Chem. 2021, doi: 10.1021/acs.jmedchem.1c00509. Link
81. Hu Y, Ma C, Szeto T, Hurst B, Tarbet B, Wang J.* Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronavirues. ACS Infect. Dis. 2021, 7, 586-597. Link
80. Hu Y, Meng X, Zhang F, Xiang Y, Wang J.* The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg. Microbes Infect. 2021,10, 317-330. Link
79. Ma C, Wang J.* Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2021, 118, e2024420118. (Letter to the editor) Link
Year 2020
78. Sacco M, Ma C, Lagarias P, Gao A, Townsend J, Meng X, Dube P, Zhang X, Hu Y, Kitamura N, Hurst B, Tarbet B, Marty M, Kolocouris A, Chen Y,* Wang J.* Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv. 2020, 6, eabe0751. Link
77. Ma C, Hu Y, Townsend J, Lagarias P, Marty M, Kolocouris A, Wang J.* (2020) Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol. Transl. Sci. 3, 1265-1277. Link
76. Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina N, Ma C, Papanastasiou I, Schreiner P, Vazques S, Schmidtke M, Wang J, Busath D, Kolocouris A.* Chemical probes for blocking of the influenza A M2 WT and S31N channels. ACS Chem. Biol. 2020, 15, 2331-2337. Link
75. Ma C, Hu Y, Zhang J, Wang J.* Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect. Dis. 2020, 6, 2260-2270. Link
74. Cai S, Tuohy P, Ma C, Kitamura N, Gomez K, Zhou Y, Ran D, Bellampalli S, Yu J, Luo S, Dorame A, Ngan P, Nancy Y, Molnar G, Streicher J, Patek M, Perez-Miller S, Moutal A, Wang J,* Khanna R.* A modulator of low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. Pain 2020, 161, 2551-2570. Link
73. Musharrafieh R, Kitamura N, Hu Y, Wang J.* Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg. Chem. 2020, 101, 103981. Link
72. Ma C, Sacco M, Hurst B, Townsend J, Hu Y, Szeto T, Zhang X, Tarbet B, Marty M, Chen Y,* Wang J.* Boceprevir, GC-376, and calpain inhibitors II and XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020, 30, 678-692. Link
71. Hu Y, Musharrafieh R, Zheng M, Wang J.* Enterovirus D68 antivirals: past, present, and future. ACS Infect. Dis. 2020, 6, 1572-1586. Link
70. Musharrafieh R, Lagarias P, Ma CL, Hau, R, Romano A, Lambrinidis G, Kolocouris A,* Wang J.* Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments. ACS Pharmacol. Trans. Sci. 2020, 3, 666-675. Link
69. Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I.* Put a cork in it: plugging the M2 viral ion channel to sink influenza. Antiviral Res. 2020, 178, 104780. Link
68. Thomaston JL, Konstantinidi A, Liu L, Lambrinidis G, Tan J, Caffrey M, Wang J, Degrado WF,* Kolocouris A.* X-ray crystal structures of the influenza M2 proton channel drug-resistant V27A mutant bound to a spiro-adamantyl amine inhibitor reveal the mechanism of amantadine resistance. Biochemistry. 2020, 59, 627-634. Link
67. Zhang, J., Hu, Y., Wu, N., Wang, J.* Discovery of influenza polymerase PA-PB1 interaction inhibitors using an in vitro split-luciferase complementation-based assay. ACS Chem. Biol. 2020, 15, 74-82. Link
Year 2019
66. Musharrafieh R, Ma C, Wang J.* Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. Eur. J. Pharm. Sci. 2019, 141, 105124. Link
65. Ma C, Zhang J, Hu Y, Musharrafieh R, Wang J.* A novel capsid binding inhibitor displays potent antiviral activity against enterovirus D68. ACS Infect. Dis. 2019, 5, 1952-1962. Link
64. Thomaston J, Wu Y, Polizzi N, Liu L, Wang J, DeGrado WF.* X-ray crystal structure of the influenza A M2 proton channel S31N mutant in two conformational states: an open and shut case. J. Am. Chem. Soc. 2019, 141, 11481-11488. Link
63. Musharrafieh R, Lagarias P, Ma C, Tan G, Kolocouris A,* Wang J.* The L46P mutant confers a novel allosteric mechanism of resistance towards the influenza A virus M2 S31N proton channel blockers. Mol. Pharmacol. 2019, 96, 148-157. Link
62. Zhang J, Hu Y, Hau R, Musharrafieh R, Ma C, Zhou X, Chen Y, Wang J.* Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses. Eur. J. Pharm. Sci. 2019, 133, 86-94. Link
61. Musharrafieh R, Zhang J, Tuohy P, Kitamura N, Bellampalli SS, Hu Y, Khanna R, Wang J.* Discovery of quinoline analogous as potent antivirals against enterovirus D68 (EV-D68). J. Med. Chem. 2019, 62, 4074-4090. Link
60. Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, Wang J.* Validating enterovirus D68 2Apro as an antiviral drug target and the discovery of telaprevir as a potent EV-D68-2Apro inhibitor. J. Virol. 2019, 93, e02221-18. (Spotlight feature article). Link
Year 2018
59. Hu Y, Hau R, Wang Y, Tuohy P, Zhang Y, Xu S, Ma C, Wang J.* Structure-property relationship studies of influenza A virus AM2-S31N proton channel blockers. ACS. Med. Chem. Lett. 2018, 9, 1111-1116. (highlighted by ScienceDaily, ACS PressPac, and EurekAlert). Link
58. Thomaston JL, Polizzi NF, Konstantinidi A, Wang J, Kolocouris A,* DeGrado WF.* (2018) Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters. J. Am. Chem. Soc. 140, 15219-15226. Link
57. Zhang J, Hu Y, Musharrafieh R, Yin H, Wang J.* Focusing on the influenza polymerase complex: recent progress in drug discovery and assay development. Curr. Med. Chem. 2019, 26, 2243-2263. Link
56. Zhao X, Li R, Zhou Y, Xiao M, Ma C, Yang Z, Zeng S, Du Q, Yang C, Jiang H, Hu Y, Wang K, Mok CKP, Sun P, Dong J, Cui W, Wang J, Tu Y, Yang Z, Hu W.* Discovery of highly potent pinanamine-based inhibitors against amantadine- and oseltamivir-resistant influenza A viruses. J. Med. Chem. 2018, 61, 5187-5198. Link
55. Mandour YM, Breitinger U, Ma C, Wang J, Boeckler FM, Breitinger HG, Zlotos DP. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7. Drug Des. Devel. Ther. 2018, 12, 1019-1031. Link
54. Zhang J, Hu Y, Foley C, Wang Y, Musharrafieh R, Xu ST, Zhang YT, Ma C, Hulme C, Wang J.* Exploring Ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance. Sci. Rep. 2018, 8, 4653. Link
53. Musharrafieh R, Ma C, Wang J.* Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res. 2018, 153, 10-22. Link
52. Drakopoulos A, Tzitzoglaki C, McGuire K, Hoffman A, Konstantinidi A, Kolokouris D, Ma C, Freudenberger K, Hutterer J, Gauglitz G, Wang J, Schmidtke M, Busath D, Kolocouris A.* Unraveling the binding, proton blockage, and inhibition of influenza M2 WT and S31N by rimantadine variants. ACS Med. Chem. Lett. 2018, 9, 198-203. Link
51. Wang Y, Hu Y, Xu S, Zhang Y, Musharrafieh R, Hau R, Ma C, Wang J.* In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses. J. Med. Chem. 2018, 61, 1074-1085. Link
50. Ma C, Wang J.* Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses. Biochim. Biophys. Acta.-Biomembrane 2018, 1860, 272-280. Link
Year 2017
49. Williams J, Shcherbakov A, Wang J, Hong M.* Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR. J. Biol. Chem. 2017, 292, 17876-17884. Link
48. Hu Y, Zhang J, Musharrafieh R, Hau R, Ma C, Wang J.* Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral. Int. J. Mol. Sci. 2017, 18, E1929. Link
47. Hu Y, Zhang J, Musharrafieh R, Ma C, Hau R, Wang J.* Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Res. 2017, 145, 103-113. Link
46. Barniol-Xicota M, Gazzarrini S, Torres E, Hu Y, Wang J, Naesens L, Moroni A, Vazquez S.* Slow but steady wins the race: dissimilarities among new dual inhibitors of the wild-type and the V27A mutatn M2 channels of influenza A virus. J. Med. Chem. 2017, 60, 3727-3738. Link
45. Hu Y, Wang Y, Fang L, Ma C, Wang J.* Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. Eur. J. Med. Chem. 2017, 135, 70-76. Link
44. Hu Y, Sneyd H, Dekant R, Wang J.* Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr. Top. Med. Chem. 2017, 17, 2271-2285. Link
43. Li F, Hu Y, Wang Y, Ma C, Wang J.* Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki–Miyaura Cross-Coupling Reaction. J. Med. Chem. 2017, 60, 1580-1590. Link
42. Drakopoulos A, Tzitzoglaki C, Ma C, Freudenberger K, Hoffmann A, Hu Y, Gauglitz G, Schmidtke M, Wang J,* Kolocouris A,* Affinity of rimantadine enantiomers against Influenza A/M2 protein Revisited. ACS Med. Chem. Lett. 2017, 8, 145-150. Link
41. Hu Y, Musharrafieh R, Ma C, Zhang J, Smee D, DeGrado WF, Wang J.* An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Res. 2017, 140, 45-54 Link
Year 2016
40. Li F, Ma C, Hu Y, Wang Y, Wang J.* Discovery of potent antivirals against amantadine-resistant influenza A viruses by targeting the M2-S31N proton channel. ACS Infect. Dis. 2016, 2, 726-133. Link
39. Ma C, Li, F, Musharrafieh R, Wang J.* Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier to drug resistance. Antiviral Res. 2016, 133, 62-72. Link
38. Ma C, Zhang J, Wang J.* Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic barrier of Drug Resistance of M2-S31N Channel Blockers. Mol. Pharmacol. 2016, mol.116.105346. Link
37. William J, Tietze D, Lee M, Wang J, Hong M.* Solid-State NMR Investigation of the Conformation, Proton Conductance, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel. J. Am. Chem. Soc. 2016, 138, 8143-8155. Link
36. Li F, Ma C, DeGrado WF, Wang J.* Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel. J. Med. Chem. 2016, 59, 1207-1216. Link
35. Wang, J.* M2 as a target to combat influenza drug resistance: what does the evidence say? Future Virology (invited editorial) 2016, 11, 1-4. Link
Year 2015
34. Li F, Ma C, Wang J.* Inhibitors Targeting the Influenza Virus Hemagglutinin. Curr. Med. Chem. 2015, 22, 1361-1382. Link
33. Wang J,* Li F, Ma C. Recent Progress in Designing Inhibitors that Target the Drug-Resistant M2 Proton Channels from the Influenza A Viruses. Biopolymers: Peptide Science. 2015, 104, 291-309. Link
Year 2014
32. Wu Y, Canturk B, Jo H, Ma C, Gianti E, Klein M, Pinto L, Lamb R, Fiorin G,* Wang J,* DeGrado WF* Flipping in the pore: Discovery of Dual Inhibitors that Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. J. Am. Chem. Soc. 2014, 136, 17987-13995. Link
At the University of California, San Francisco (Postdoc work)
31. Ghosh, A., Wang, J., Moroz, Y. S., Korendovych, I. V., Zanni, M. T., DeGrado, W. F., and Hochstrasser, R. M. 2D IR Spectroscopy Reveals the Role of Water in the Binding of Channel-Blocking Drugs to the Influenza M2 Channel. J. Chem. Phys. 2014, 40, 235105.
30. Montalvo, G. L., Zhang, Y., Young, T. M., Costanzo, M. J., Freeman, K. B., Wang, J., Clements, D. J., Magavern, E., Kavash, R. W., Scott, R. W., Liu, D., and DeGrado, W. F. De Novo Design of Self-Assembling Foldamers That Inhibit Heparin-Protein Interactions. ACS Chem. Biol. 2014, 9, 967-975.
29. Rey-Carrizo, M., Torres, E., Ma, C., Barniol-Xicota, M., Wang, J., Wu, Y., Naesens, L., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. M2 ion channel of influenza A virus: from wild-type inhibitors to compounds with potent activity against the V27A mutant. J. Med. Chem. 2013, 56, 9265-9274.
28. Ma, C. L., Fiorin, G., Carnevale, V., Wang, J., Lamb, R. A., Klein, M. L., Wu, Y. B., Pinto, L. H., and DeGrado, W. F. Asp44 stabilizes the Trp41 gate of the M2 proton channel of influenza A virus. Structure 2013, 21, 2033-2041.
27. Wang, J., Wu, Y., Ma, C., Fiorin, G., Wang, J., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 1315-1320. Highlighted by Science-Business eXchange (SciBX).
26. Williams, J. K., Tietze, D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR. J. Am. Chem. Soc. 2013, 135, 9885-9897. Highlighted by JACS.
25. Wang, J., Ma, C., Wang, J., Jo, H., Canturk, B., Fiorin, G., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J. Med. Chem. 2013, 56, 2804-2812.
24. Thomaston, J. L., Nguyen, P. A., Brown, E. C., Upshur, M. A., Wang, J., DeGrado, W. F., and Howard, K. P. Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling. Protein Sci. 2013, 22, 65-73.
23. Schmidt, N. W., Mishra, A.,# Wang, J.,# DeGrado, W. F., and Wong, G. C. Influenza virus a m2 protein generates negative gaussian membrane curvature necessary for budding and scission. J. Am. Chem. Soc. 2013, 135, 13710-13719.
22. Mao, L., Wang, J., DeGrado, W. F., and Inouye, M. An assay suitable for high throughput screening of anti-influenza drugs. Plos One 2013, 8, e54070
21. Balgi, A. D.,# Wang, J.,# Cheng, D. Y., Ma, C., Pfeifer, T. A., Shimizu, Y., Anderson, H. J., Pinto, L. H., Lamb, R. A., DeGrado, W. F., and Roberge, M. Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay. Plos One 2013, 8, e55271.
At the University of Pennsylvania (PhD work)
20. Wang, J., Qiu, J. X., Soto, C., and DeGrado, W. F. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr. Opin. Struct. Biol. 2011, 21, 68-80.
19. Wang, J., Ma, C., Wu, Y., Lamb, R. A., Pinto, L. H., and DeGrado, W. F. Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J. Am. Chem. Soc. 2011, 133, 13844-13847. Highlighted by Faculty 1000.
18. Wang, J., Ma, C., Fiorin, G., Carnevale, V., Wang, T., Hu, F., Lamb, R. A., Pinto, L. H., Hong, M., Klein, M. L., and DeGrado, W. F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J. Am. Chem. Soc. 2011, 133, 12834-12841. Highligted by Faculty 1000.
17. Wang, J., Ma, C., Balannik, V., Pinto, L. H., Lamb, R. A., and DeGrado, W. F. Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. ACS Med. Chem. Lett. 2011, 2, 307-312.
16. Rogers, J. M., Polishchuk, A. L., Guo, L., Wang, J., DeGrado, W. F., and Gai, F. Photoinduced electron transfer and fluorophore motion as a probe of the conformational dynamics of membrane proteins: application to the influenza a M2 proton channel. Langmuir 2011, 27, 3815-3821.
15. Duque, M. D., Ma, C., Torres, E., Wang, J., Naesens, L., Juarez-Jimenez, J., Camps, P., Luque, F. J., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J. Med. Chem. 2011, 54, 2646-2657.
14. Cady, S. D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J. Am. Chem. Soc. 2011, 133, 4274-4284.
13. Leiding, T., Wang, J., Martinsson, J., DeGrado, W. F., and Arskold, S. P. Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 15409-15414.
12. Cady, S. D., Schmidt-Rohr, K., Wang, J., Soto, C. S., DeGrado, W. F., and Hong, M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463, 689-692.
11. Balannik, V., Obrdlik, P., Inayat, S., Steensen, C., Wang, J., Rausch, J. M., DeGrado, W. F., Kelety, B., and Pinto, L. H. Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. Pflugers Archiv : European journal of physiology 2010, 459, 593-605.
10. Wang, J., Cady, S. D., Balannik, V., Pinto, L. H., DeGrado, W. F., and Hong, M. Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J. Am. Chem. Soc. 2009, 131, 8066-8076. Highlighted by ACS Chemical Biology.
9. Balannik, V.,# Wang, J.,# Ohigashi, Y., Jing, X., Magavern, E., Lamb, R. A., DeGrado, W. F., and Pinto, L. H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 2009, 48, 11872-11882.
At the National University of Singapore (Master work)
8. Uttamchandani, M., Wang, J., Li, J., Hu, M., Sun, H., Chen, K. Y., Liu, K., and Yao, S. Q. Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. J. Am. Chem. Soc. 2007, 129, 7848-7858.
7. Uttamchandani, M., Lee, W. L., Wang, J., and Yao, S. Q. Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays. J. Am. Chem. Soc. 2007, 129, 13110-13117.
6. Wang, J., Uttamehandani, M., Sun, H. Y., and Yao, S. Q. Small molecule microarrays: Applications using specially tagged chemical libraries. QSAR Comb. Sci. 2006, 25, 1009-1019.
5. Wang, J., Uttamchandani, M., Sun, L. P., and Yao, S. Q. Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays. Chem. Commun. 2006, 717-719.
4. Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. Rapid assembly of matrix metalloprotease inhibitors using click chemistry. Org. Lett. 2006, 8, 3821-3824.
3. Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. “Click” synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases. Chem. Commun. 2006, 3783-3785. Highlighted as ‘hot paper’ by Chem. Commun., Chemical Society Magazine and Chemistry World.
2. Uttamchandani, M., Wang, J., and Yao, S. Q. Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Mol. Biosyst. 2006, 2, 58-68.
1. Sun, H., Chattopadhaya, S., Wang, J., and Yao, S. Q. Recent developments in microarray-based enzyme assays: from functional annotation to substrate/inhibitor fingerprinting. Anal. Bioanal. Chem. 2006, 386, 416-426.
Patents
Three invention disclosures at Rutgers: DISC-2023-098 Therapeutic compounds (provisional application filed, U.S. 63/447,269), 2023-075 and 2023-066 (pending).
Wang, J. Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection. US20220332683A1.
Wang, J., Kitamura, N. Compositions and methods for inhibiting viral protein 2C activity for preventing and treating non-polio enterovirus infection. US20220306627A1. (pending)
Wang, J., Hu, Y., Ma, C.L., Kitamura, N. Compositions and methods for inhibiting PLpro protease activity and for preventing and treating SARS-CoV-2 infection. WO2022192665A1.
Wang, J., Kitamura, N., Ma, C.L. Compositions and methods for inhibiting Mpro protease activity and for preventing and treating SARS-CoV-2 infection. WO2022119756A1.
Wang, J., Ma, C.L. Small molecule inhibitors of SARS-CoV-2 viral replication and uses thereof. WO2021207409A2
Wang, J., Rajesh Khanna. Small molecule inhibitors of Cav3.2 activity and uses thereof. WO2021231553A1.
Wang, J., Musharrafieh, R., Ma, C.L., Zhang, J.T., Hu, Y.M. Small molecule enterovirus inhibitors and uses thereof. US20210244721A1
Wang, J., Ma, C.L., Hulme, C. Methods and compositions for the treatment of influenza. US2019089734A1.
DeGrado, W. F., Wang, J, Wang, J., Jo, H., Canturk, B. Inhibitors targeting drug-resistant influenza A. US9884832B2
DeGrado, W. F., Wang, J. Influenza A virus inhibition. US9464075B2
DeGrado, W. F., Wang, J. Inhibition of influenza A virus M2 proton channel. US9453005B2
DeGrado, W. F., Wang, J. Adamantane analogs. US9301950B2
DeGrado, W. F., Wang, J. Inhibitors of the influenza A virus M2 proton channel. US8569284B2
DeGrado, W. F., Wang, J. Spiro-piperidine inhibitors. US8557836B2